A detailed history of Royal Bank Of Canada transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Royal Bank Of Canada holds 463 shares of BCYC stock, worth $9,472. This represents 0.0% of its overall portfolio holdings.

Number of Shares
463
Previous 463 -0.0%
Holding current value
$9,472
Previous $9,000 11.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.02 - $24.69 $3,523 - $4,345
176 Added 61.32%
463 $9,000
Q1 2024

Nov 05, 2024

SELL
$16.75 - $26.1 $2,948 - $4,593
-176 Reduced 38.01%
287 $7,000
Q1 2024

May 15, 2024

SELL
$16.75 - $26.1 $988 - $1,539
-59 Reduced 17.05%
287 $7,000
Q4 2023

Feb 14, 2024

SELL
$13.29 - $22.2 $2,511 - $4,195
-189 Reduced 35.33%
346 $6,000
Q3 2023

Nov 14, 2023

BUY
$19.9 - $26.25 $3,044 - $4,016
153 Added 40.05%
535 $10,000
Q2 2023

Aug 14, 2023

BUY
$18.95 - $28.67 $3,581 - $5,418
189 Added 97.93%
382 $9,000
Q1 2023

May 15, 2023

SELL
$20.02 - $31.37 $360 - $564
-18 Reduced 8.53%
193 $4,000
Q4 2022

Feb 14, 2023

BUY
$20.37 - $32.9 $61 - $98
3 Added 1.44%
211 $6,000
Q3 2022

Nov 14, 2022

BUY
$17.49 - $28.44 $314 - $511
18 Added 9.47%
208 $4,000
Q2 2022

Aug 15, 2022

SELL
$12.95 - $46.99 $738 - $2,678
-57 Reduced 23.08%
190 $3,000
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $3,851 - $5,712
96 Added 63.58%
247 $11,000
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $1,959 - $2,873
47 Added 45.19%
151 $9,000
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $2,906 - $4,600
104 New
104 $4,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $607M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.